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Uncontrolled diabetes mellitus is the seventh leading cause of mortality and the leading cause of 
blindness, kidney failure, and non-traumatic amputations in the United States. A high prevalence 
of type 2 diabetes mellitus (T2D) has placed a strain on health care systems due to costs 
associated with anti-diabetic medications as well as diabetes-associated morbidities and 
disabilities. Traditionally, medical care providers have prescribed lifestyle and medication 
changes during clinical face-to-face visits, however these visits are costly and are often not 
effective for producing desired changes in self-management techniques. Evidence shows that the 
current standard of care often fails to deliver on achieving evidence-based recommendations for 
glycemic control for patients with diabetes. Recent advancements in telemedicine technologies 
have emerged as promising platforms which can deliver diabetes management services while 
reducing unnecessary use of health care resources. Different technological approaches may vary 
with regard to patient glycemic control outcomes, and cost differences should be taken into 
consideration when selecting the technology that may provide the greatest overall benefit for the 
patient. Many newer glucometers have transmission capabilities, allowing these meters to link to 
smartphone Apps or websites. Patients can measure their glucose levels, share results with their 
healthcare team in real time, and talk over the phone or through video visits for medication or 
lifestyle interventions, all in a more expedient manner compared to traditional face-to-face visits. 
Remote monitoring of blood glucose levels by clinicians has been shown to be feasible and 
acceptable for patients with both type 1 diabetes mellitus (T1D) and T2D. With this background 
in mind, the aim of the current review was to evaluate the effectiveness of remote blood glucose 
monitoring compared to continuous glucose monitoring (CGM) for lowering HbA1c in adult 
patients with T2D. PubMed was searched for randomized controlled trials, clinical trials, and 
  
systematic reviews that included either remote blood glucose monitoring, CGM, or both, and 
individual interventions had to be longer than six weeks in duration. Studies also had to include 
adult patients with T2D and had to examine the outcome of change in HbA1c as the primary or 
secondary outcome of interest. Inclusion and exclusion criteria were determined a priori, and 
searches included a variety of search terms yielding 92 records, of which 27 articles met the 
inclusion criteria. Study findings suggested that both remote blood glucose monitoring and CGM 
are effective for reducing HbA1c in patients with T2D compared to controls. Both the absolute 
treatment means, and the average treatment mean differences suggest larger reductions in HbA1c 
in the remote blood glucose monitoring interventions as compared to the CGM interventions. In 
agreement with previous research, side by side comparisons of the included studies revealed a 
trend toward greater absolute reductions in HbA1c among all studies where patients had higher 
baseline HbA1c levels, frequent engagement with the clinical team for more timely and 
responsive management, as well as algorithm-based treatment plans. Future studies should 
include a comparison of feasibility, cost of care to implement the interventions, and cost savings 
to inform clinical decision making, thereby identifying the technology with the greatest overall 
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Chapter 1 - Introduction 
In the United States, uncontrolled diabetes mellitus is the seventh leading cause of 
mortality and the leading cause of blindness, kidney failure, and non-traumatic amputations.1 In 
2017, the Centers for Disease Control and Prevention reported that approximately 30.3 million 
adults in the United States were affected by diabetes mellitus, which is about one in every ten 
adults, 95% of whom are diagnosed with type 2 diabetes mellitus (T2D).2 The American 
Diabetes Association’s standard glycemic control target of Hemoglobin A1c (HbA1c) level is 
less than 7%.3 Research shows that fewer than 65% of patients who have T2D achieve the 
optimal HbA1c target, and many patients have suboptimal glucose control despite clear evidence 
that good glycemic control can prevent diabetic complications.1, 3, 4, 5 
A high prevalence of T2D has placed a strain on health care systems due to costs 
associated with anti-diabetic medications as well as diabetes-associated morbidities and 
disabilities.4 Long-term macrovascular and microvascular complications such as myocardial 
infarction and kidney failure are responsible for most morbidities and mortality in patients with 
diabetes.7, 8 The International Diabetes Federation estimates that health care costs for patients 
with T2D are two to three times higher than patients of similar age and sex without diabetes.8 
Large-scale randomized trials have shown that microvascular complications can be reduced with 
optimal glycemic control, and by reducing the incidence of chronic complications, costs can also 
be substantially reduced.7 
Many patients with diabetes face barriers regarding adequate self-management and 
adherence to treatment plans, including lifestyle changes. Previous research suggests that one-
on-one counseling focused on lifestyle interventions has a positive impact on diabetes outcomes, 
but high cost and time commitment are major challenges for successful intervention.5 
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Traditionally, medical care providers prescribe lifestyle and medication changes during clinical 
face-to-face visits three to six times per year, however these visits are costly and are often not 
effective for producing desired changes in self-management techniques.5, 6, 8, 9 Evidence shows 
that the current standard of care often fails to deliver on achieving evidence-based 
recommendations for glycemic control for patients with diabetes.5, 8 
With ongoing technological innovation, there is growing interest in leveraging new 
medical technologies to support diabetes management and to compliment traditional in-person 
care, especially in remote areas where access to care is limited.2 Recent advancements in 
telemedicine technologies have emerged as promising platforms which can deliver diabetes 
management services while reducing unnecessary use of health care resources.5, 7 Telemedicine 
approaches vary, but many use telecommunication methods such as phone calls and video visits 
to deliver services.10 Telemedicine can provide remote consultations, personalized diet and 
lifestyle advice, and remove transportation barriers. These approaches are becoming more 
feasible since mobile phones are widely used across socioeconomic groups, making them 
promising tools for healthcare delivery.11 Some studies with heterogeneous sample sizes and 
ethnicities have provided evidence that telemedicine may improve care for patients with 
diabetes, particularly with regard to remote monitoring and feedback related to glucose 
concentrations, lifestyle management programs, and video-based education programs.7, 12  
The American Diabetes Association recommends that people with diabetes mellitus 
perform self-monitoring of blood glucose (SMBG) four to eight times daily until normoglycemia 
is achieved.13 Traditionally, glucose assessment is performed by drawing a small amount of 
capillary blood from a fingertip, and using a portable glucometer to analyze the blood droplet for 
glucose content.13 Few patients adhere to the recommended measurement frequency due to pain, 
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hassle of testing, and limited utility of results.13 The cost of SMBG supplies might also be a 
barrier to adherence. Other limitations are that SMBG provides only a snapshot of current 
glucose levels, with many highs and lows going undetected and untreated.13 In standard practice, 
patients must remember to bring their SMBG log to their clinical face-to-face visit where 
provider-directed adjustments may take place, although considerable evidence shows that 
clinicians fail to follow clinical practice guidelines and recommendations.5, 6, 8, 9 Together, this 
evidence suggests that barriers to traditional SMBG limit successful management of T2D.  
New payment models that reimburse providers based on outcomes rather than fees for 
services, are driving the exploration of new service delivery methods that result in improved 
patient outcomes.5, 9 Telemedicine is one method of particular interest, where clinicians utilize 
technology to deliver care from a distance.2 There is heterogeneity in the tools and delivery 
methods used by clinicians, which can range widely from one practice to the next. Some 
clinicians use smartphone applications (Apps) or websites which may contain sophisticated 
learning modules, synchronous messaging, asynchronous messaging, video visit capabilities, or 
machine learning clinical algorithms to guide clinical decision making. Other clinicians use far 
less sophisticated tools and may only use telephone calls with either structured or unstructured 
patient interactions.  
Many newer glucometers have transmission capabilities, allowing these meters to link to 
smartphone Apps or websites for remote monitoring by clinicians. There is heterogeneity in the 
tools and delivery methods, but typically patients can measure their glucose levels, share results 
with their healthcare team in real time, and talk via the phone or through video visits for 
medication or lifestyle interventions, all in a more expedient manner compared to traditional 
face-to-face visits. Remote monitoring of blood glucose levels by clinicians is one aspect of 
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telemedicine, and has been shown to be feasible and acceptable for patients with both type 1 
diabetes mellitus (T1D) and T2D.13 The use of these services has been shown to be beneficial for 
weight loss, reducing HbA1c levels, supporting behavior change, increasing patient self-efficacy, 
and improving ability for patient self-management of their disease.2 For the purpose of the 
current review, we will use the term remote blood glucose monitoring to encompass studies that 
include SMBG and transmission of glucose data to a clinician, combined with at least one 
telemedicine delivery method. 
A newer technology for testing blood glucose is the use of a Continuous Glucose 
Monitoring System (CGM) which measures interstitial fluid glucose levels from a thin needle 
attached to a small sensor, which is typically worn on the back upper arm or abdomen for up to 
two weeks at a time.13 CGM provides real-time data, updating every five to 15 minutes, allowing 
for the determination of velocity and direction of glucose changes.13 CGM does not require 
finger pricks and can detect fluctuations in blood glucose that are often missed with traditional 
SMBG, such as overnight lows and postprandial highs. By viewing daily CGM trends, clinicians 
can improve medication titration, and reduce the occurrence of severe hypoglycemic and 
hyperglycemic events compared with SMBG.13 
Since 2008, The American Diabetes Association “Standards of Medical Care in 
Diabetes” recommendations has included CGM as an adjunct tool to SMBG for certain 
individuals, such as patients with T1D and those with hypoglycemia unawareness.12 Most CGM 
research has examined the effectiveness of CGM for reducing HbA1c in patients with T1D, 
however, benefits for patients with T2D have also been of interest. 4, 12 Research is ongoing to 
investigate the use of CGM for T2D outcomes.4, 12 With technological advancements, expanding 
insurance coverage, and increasing prevalence of T2D in the United States, clinicians may 
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benefit from greater elucidation of the effectiveness of CGM for achieving HbA1c targets in 
addition to reducing T2D complications.  
Telemedicine has been shown to improve adherence to treatment plans, quality of 
services, allocation and use of healthcare resources, and delivery of more timely and appropriate 
diabetes care regardless of the patient’s location.14 Further, with remote monitoring, therapy 
effectiveness can be checked and adjusted in a timely and responsive manner.14 Two different 
telemedicine technologies, remote blood glucose monitoring and CGM, may differ with regard to 
effectiveness for patients with diabetes. Therefore, the purpose of this critical review was to 
compare the effectiveness of remote blood glucose monitoring to CGM for lowering HbA1c in 
adult patients with T2D. Our hypothesis was that in patients with T2D, CGM would be more 
effective for improving HbA1c as compared with remote blood glucose monitoring. We believed 
this newer technology, with a continuous view of glucose values may result in better awareness 
of glucose trends, and more timely interventions including lifestyle change, resulting in greater 
reductions in HbA1c. This critical review will provide important information for clinicians and 
patients regarding the strengths and limitations of each treatment technology in order to assist 
with clinical decision making, thereby providing the most clinical benefit for the patient, with 














Chapter 2 - Methods 
In order to achieve the study purpose, we performed a search for relevant studies in the 
published literature indexed in PubMed. Inclusion and exclusion criteria were determined a 
priori. We included randomized controlled trials, clinical trials, and systematic reviews. These 
studies included either remote blood glucose monitoring, CGM, or both, and had to be longer 
than six weeks in duration. Studies also had to include adult patients with T2D and had to 
examine the outcome of change in HbA1c as the primary or secondary outcome of interest. 
Studies were excluded when only T1D patients were included or when T1D and T2D results 
were not able to be differentiated. Studies that were focused on insulin management or 
medication titration were also excluded, as were studies that included only pediatric populations.  
Relevant studies for inclusion were obtained through searching PubMed using a variety 
of search terms. Five records were identified using the search terms “telemedicine” [MeSH] 
AND “blood glucose self-monitoring/instrumentation” [MeSH] NOT “insulin infusion systems” 
[MeSH] NOT ‘diabetes mellitus, type 1” [MeSH] NOT “child” [MeSH]. Thirty-one records were 
identified using the search terms “diabetes mellitus, type 2” [MeSH] AND “blood glucose self-
monitoring/instrumentation” [MeSH] NOT “insulin infusion systems” [MeSH] NOT “diabetes 
mellitus, type 1” NOT “child” [MeSH]. Twenty-one records were identified using the search 
terms “telemedicine/methods” [MeSH] AND “blood glucose self-monitoring/methods” [MeSH] 
NOT “insulin infusion systems” [MeSH] NOT “diabetes mellitus, type 1” [MeSH] NOT “child” 
[MeSH]. Thirty-five records were identified using search terms “diabetes mellitus, type 2” 
[MeSH] AND “blood glucose self-monitoring” [MeSH] AND “glycated hemoglobin a/analysis” 
[MeSH]. Filters were applied to limit searches to the highest quality studies and included 
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“humans”, “clinical trial”, “randomized controlled trial”, and “systematic review”. Following 
removal of duplicates, 82 records remained.  
 Manual screening of abstracts resulted in removal of 57 records, and a full text article 
review resulted in removal of 6 records due to a priori exclusion criteria. Reasons for exclusion 
were varied and can be seen in detail in Figure 1. Eighteen experimental studies and one 
systematic review matched our eligibility criteria. The systematic review was hand searched for 
individual studies that also fit the eligibility criteria, resulting in nine additional studies. A total 
of 27 experimental studies were included in our final descriptive critical analysis. 
 Statistical Analysis  
While our intention was not to perform a meta-analysis given the lack of studies that 
directly compared remote blood glucose monitoring and CGM, we determined the change in 
HbA1c for the control and experimental groups in order to quantitatively determine any potential 
advantages for one technology, indirectly compared with the other, for patients with T2D. We 
utilized Google Sheets to perform our statistical analysis. The mean change in HbA1c, as 
reported using the Diabetes Control and Complications Trial (DCCT) percentage units, was 
compared between the control and the experimental groups for each study.32 In addition, we 
calculated the mean difference in change in HbA1c between the control and experimental 
groups, the standard deviation, the interquartile range, the median effects as the central tendency 
for the change in HbA1c, and the range of the overall effects. For our primary results, we 
compared the average effects for remote blood glucose monitoring to the average effects for 
CGM to get a sense of whether there are clinically meaningful differences in effectiveness 
regarding HbA1c outcomes when using these two different monitoring technologies.   
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Chapter 3 -  Results 
A total of 21 studies using remote blood glucose monitoring met the criteria for inclusion, 
all of which indicated reductions in HbA1c within their treatment groups. Of the studies that 
reported patient age, ages ranged from 40 to 86. The duration of the interventions ranged from 
three to 60 months. The mean change in HbA1c within the treatment groups was -1.01% with a 
median of -1.00%, standard deviation of 0.60, and interquartile range of 0.60. The mean change 
in HbA1c within the control groups was -0.34% with a median of -0.27%, standard deviation of 
0.42, and interquartile range of 0.50. Two of the 21 studies did not include a control group. Of 
the 19 studies that included a control group, 16 showed a reduction in HbA1c, and three 
indicated an increase in HbA1c. The mean differences in changes in HbA1c between the 
treatment groups and control groups ranged from 0.01% to -1.10% with a standard deviation of 
0.35 and interquartile range of 0.55. The average mean difference was -0.56%, favoring the 
remote blood glucose monitoring treatment group over the control condition with a median 
difference of -0.52%. (See Table 3.1) 
A total of six studies using CGM met the criteria for inclusion, all of which indicated 
reductions in HbA1c within their treatment groups. Of the studies that reported patient age, ages 
ranged from 26 to 79. The duration of the interventions ranged from two to six months. The 
mean change in HbA1c within the treatment group was -0.92% with a median of -0.9%, standard 
deviation of 0.61, and interquartile range of 0.54. The mean change in HbA1c within the control 
groups was -0.56% with a median of -0.71%, standard deviation of 0.45, and interquartile range 
of 0.38. Two studies did not include a control group. Of the four studies that included a control 
group, one used the same participants to compare SMBG frequency with CGM. Three of the 
studies resulted in a statistically significant reduction in HbA1c, and one study showed an 
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increase in HbA1c. The mean differences in changes in HbA1c between the treatment groups and 
control groups ranged from 0.1% to -0.43% with a standard deviation of 0.27 and interquartile 
range of 0.32. The average mean difference was -0.26%, favoring the CGM treatment group over 
the control condition with a median difference of -0.31%. (See Table 3.2) 
There was heterogeneity in the types of devices used for both remote blood glucose 
monitoring and CGM. For remote blood glucose monitoring there were six different modes by 
which data were delivered to clinicians. The most frequent type described were devices that 
uploaded data to clinicians, used in 43% of studies. For CGM there were four different modes by 
which data were delivered to clinicians. The most frequent type described were Dexcom and 















Figure 3.1. PRISMA Flow Diagram 
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Figure 3.2. Clinician Breakout Box 






• While evidence clearly shows that improved glycemic control can prevent diabetic 
complications, the current standard of care is failing to meet optimal HbA1c targets for 
T2D patients.1, 3, 4 
 
• The current critical review suggested that both remote blood glucose monitoring and 
CGM are effective for reducing HbA1c in T2D patients compared to controls. 
 
• Contrary to our hypothesis, both the absolute treatment means, and the average treatment 
mean differences suggested a larger reduction in HbA1c in the remote blood glucose 
monitoring interventions as compared to the CGM interventions. 
 
• Side by side comparisons of the included studies revealed a trend toward a greater 
absolute reduction in HbA1c in studies, in agreement with previous research, where 
patients had higher starting HbA1c levels, frequent engagement with the clinical team for 
more timely and responsive management, as well as algorithm-based treatment plans. 
 
• Insurance coverage and cost differences between the two technologies should be taken 






Table 3.1.  Remote Blood Glucose Monitoring Study Results  
Remote Blood Glucose Monitoring Study Results  
 





± SD  
Absolute Change 
in HbA1c Control 
Group (%) 





± SE (%) 
p-value 
Greenwood et al,1 2015 90 6 8.3 ± 1.1 -0.70 -1.11  -0.41 ± 0.08 0.009 
Storch et al,5 2019  115 3 6.9 ± 1.01 0.05 -0.47 -0.52 ± 0.17 0.038 
Jeong et al,7 2018 338 6 8.3 ± 1.14 -0.66 -0.81 -0.15 0.162 
Wild et al,8 2016 321 9 8.9 ± 1.3 -0.40 -1.00 -0.60 0.007 
Watson et al,6 2009  7 3 6.8 X -1.00 X NR 
Sun et al,10 2019 91 6 7.9 -0.38 -1.00 -0.62 0.020 
Dario et al,14 2017 299 12 7.9  -0.27 -0.26 0.01 0.760 
Lee et al,20 2017 85 3 8.7 ± 1.1 -0.24 -1.07 -0.83 <0.01 
B-Fedak et al,21 2011 100 6 7.6 -0.01 -0.29 -0.28 0.720 
Tildesley et al,22 2011 50 12 8.6 -0.10 -1.20 -1.10 0.350 
Cho et al,23 2006 80 30 7.6 -0.10 -1.00 -0.90 0.022 
Kwon et al,24 2004 110 3 7.4 0.33 -0.54 -0.87 ± 0.13 <0.001 
Ralston et al,25 2009  83 12 8.1 0.20 -0.90 -1.10 <0.01 
Shea et al,26 2009  1665 60 7.4 -0.06 -0.31 -0.25 ± 0.06 0.001 
Biermann et al,27 2002 43 8 8.2 -1.20 -1.20 0 NR 
Stone et al,28 2010 150 6 9.5 -0.80 -1.70 -0.90 <0.001 
Bind et al,29 2007 62 6 7.1 -0.10 -0.60 -0.50 <0.01 
McMahon et al,30 2005  104 12 10.0 ± 0.8 -1.20 -1.60 -0.40 <0.05 
Magee et al,31 2016  89 3 11.3 X -3.00 X NR 
Parsons et al,9 2019  446 12 8.6 ± 1.15 -0.30 -1.20 -0.90 <0.0001 
Nagrebetsky et al,11 2013  14 12 8.1 ± 1.1 -0.50 -0.90 -0.40 0.35 
Note X indicates no control group was part of the study; NR indicates data was not reported; Absolute Change in HbA1c Treatment Group (%) - 




Table 3.2.  CGM Study Results  
CGM Study Results  
 
Note X indicates no control group was part of the study; NR indicates data was not reported; Absolute Change in HbA1c Treatment Group (%) - 











in HbA1c Control 
Group (%) 







Ajjan et al,4 2019 148 6 8.7 ± 1.0 0.10 -0.40  -0.50 ± 0.16  0.004 
Puhr et al,13 2018 175 6 8.6 -0.90 -0.80 0.10 NR  
Yeoh et al,12 2018 30 3 9.9 ± 1.2 -0.80 -1.00 -0.20 0.869 
Thielen et al,17 2010 10 6 9.6 X -2.05 X NR 
Billings et al,18 2018 316 6 8.5 ± 0.6 -0.63 -1.05 -0.43 NR 
Zick et al,19 2007 367 2 6.9 ± 0.7 X -0.23 X NR 
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Table 3.3.Types of Devices 
Types of Devices 
 
Described Device Study 
Libre  Ajjan et al,4 2019 
Dexcom  Puhr et al,13 2018 
 Billings et al,
18 2018 
Medtronix  Yeoh et al,12 2018 
 Zick et al,
19 2007 
CGM Thielen et al,17 2010 
USB Cables Greenwood et al,1 2015 
Uploaded Storch et al,5 2019 
 Watson et al,
6 2009 
 Parsons et al,
9 2019 
 Tildesley et al,
22 2011 
 Cho et al,
23 2006 
 Kwon et al,
24 2004 
 Ralston et al,
25 2009 
 Shea et al,
26 2009 
 McMahon et al,
30 2005 
Transmitted Jeong et al,7 2018 
 Dario et al,
14 2017 
 B-Fedak et al,
21 2011 
 Biermann et al,
27 2002 
 Stone et al,
28 2010 
Bluetooth  Wild et al,8 2016 
 Sun et al,
10 2019 
 Nagrebetsky et al,
11 2013 
 Lee et al,
20 2017 
Entered Online  Bind et al,29 2007 







Chapter 4 - Discussion 
The purpose of this critical review was to elucidate the effectiveness of remote blood 
glucose monitoring compared to CGM for lowering HbA1c in adult patients with T2D. Given 
the evidence suggesting that patients with T2D often do not meet glycemic control targets, and 
considering the new medical technologies to support diabetes management, we aimed to evaluate 
the available research in order to assist clinical decision making that results in the most benefit 
for the patient in terms of clinical outcomes.  
Our hypothesis was that in patients with T2D, CGM would be more effective for 
improving HbA1c. However, the studies included in this review did not support our hypothesis. 
Both the absolute treatment means, and the average treatment mean differences suggested a 
larger reduction in HbA1c in the remote blood glucose monitoring interventions as compared to 
the CGM interventions, though no studies actually included direct comparisons of these two 
technologies. Overall, our findings suggested that both remote blood glucose monitoring and 
CGM are effective for reducing HbA1c in T2D, with the largest effects seen in the remote blood 
glucose monitoring interventions.  
Side by side comparisons of included studies revealed a trend towards a greater absolute 
reduction in HbA1c in studies that had a higher starting HbA1c, frequent engagement with the 
clinical team, and algorithm-based treatment plans. While the CGM groups had access to real-
time glucose levels around the clock, which we speculated would result in greater improvement 
in HbA1c, our hypothesis was not supported possibly due to more frequent engagement by 




 Comparison to a previous Systematic Review  
The results from our review aligned well with a previously published 2015 systematic 
review which focused on remote blood glucose monitoring in T1D and T2D.3 Authors of the 
systematic review hypothesized that patients in remote blood glucose monitoring groups would 
test their glucose more often than the control groups.3 The benefit of SMBG as an explanation 
for improvements in HbA1c was examined. Increased SMBG use was expected with remote 
blood glucose monitoring, however, several studies showed no correlation with frequency of 
SMBG and improvements in HbA1c.3 The systematic review concluded that SMBG may 
contribute to improved glycemic control, but does not fully explain the benefits of remote blood 
glucose monitoring.3 Patients using remote blood glucose monitoring reported increased self-
motivation because they were being monitored more closely by their healthcare provider.3 A 
significant association between data upload frequency and improvement in HbA1c was observed, 
providing a quantitative measure of self-motivation, which correlated well with the effectiveness 
of remote blood glucose monitoring.3  
Most individual studies included in our review, as well as those included in the 
aforementioned systematic review, were short in duration. However, two studies from the 
systematic review demonstrated that remote blood glucose monitoring can help lower and 
maintain HbA1c levels over several years compared to control groups.3 While insulin dose 
changes have the potential to lower HbA1c, several studies from the systematic review 
demonstrated improvements in HbA1c that were independent of insulin dose adjustments, 
reinforcing the benefit of lifestyle interventions as important factors supporting remote blood 
glucose monitoring.3 
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The included systematic review identified several studies that included patients with over 
8% HbA1c at baseline. They found greater improvements in HbA1c in the intervention groups, 
which was also observed in the current review.3 The systematic review also identified several 
studies that included patients with low HbA1c at baseline. Results still showed greater 
improvements in the intervention group with a significant decrease in mean HbA1c of 6.70% to 
6.50% (p=.045), compared to no significant change in HbA1c in the control group.3 The 
systematic review concluded patients with a range of HbA1c could benefit from remote blood 
glucose monitoring and low HbA1c at baseline was not a limitation.3  
 Remote Blood Glucose Monitoring 
Our review included a total of 21 studies that used remote blood glucose monitoring, all 
of which indicated reductions in HbA1c within the treatment groups. Absolute reductions in 
HbA1c ranged from a of high of 3.00% to a low of .26%. The remote blood glucose monitoring 
study with the largest effect for HbA1c reduction of 3.00% used an intensive algorithm-based 
diabetes medication management program along with education and communication from the 
clinical care team which may explain why results were so high.31 The study did not have a 
control group and therefore mean difference was not calculated.31 There were similarities 
between this study and the CGM study with the largest effect on HbA1c reduction. In the CGM 
study, which took place in Belgium, an educational program combined with CGM was 
administered to a very small sample size of six participants who completed three months of the 
study, of which only four participants continued on to complete the entire six month duration of 
the study.17 The study did not include a control group, therefore a mean difference was not 
calculated.17 The intensive nature of both the remote blood glucose monitoring study and CGM 
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study interventions along with targeting a small sample, may have allowed for individualized 
attention and therefore may not be reflective of most interventions used in clinical practice. 
One remote blood glucose monitoring study provided a two-hour education class and 
timely messaging or telephone follow-up with education or medication adjustments based on 
remotely transmitted glucose data over a six-month intervention period.28 The intervention 
resulted in an average absolute reduction of 1.70% in HbA1c, which was among the largest 
reductions reported in our review. Another study, with results showing similar effectiveness, 
provided a half-day education class and used treatment algorithms combined with messaging or 
telephone follow-up based on remotely transmitted glucose data over a 12-month intervention 
duration.30 In this study, the control group, who also participated in the half-day education class, 
also saw a substantial improvement with an average absolute reduction of 1.20% in HbA1c.30  
Six studies had similar average absolute reductions in HbA1c, ranging from 1.11% to 
1.00%, and similar treatment methods.1, 6, 8, 10, 20, 23 One study provided monthly telephone calls 
to discuss remotely transmitted data and make treatment changes over six months.1 One study 
took place over three months during Ramadan and provided telephone calls to discuss remotely 
transmitted data.20 An alarm system was also used to notify the clinical team of three consecutive 
hypoglycemic readings.20 One study provided clinician messaging and recommendations every 
two weeks based on remotely transmitted data over 30 months.23 One study provided personal 
messaging with advice and reminders based on remotely transmitted data every two weeks over 
the course of six months.10 One study was based in the United Kingdom and provided treatment 
and lifestyle advice over the phone based on remotely transmitted data over the course of nine 
months.8 And one study was a pilot study with no control group and only included seven 
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participants, but provided personal messaging with feedback based on remotely transmitted data 
over three months.6  
Several studies had similar treatment group methods, with clinicians sending individual 
feedback and making medication adjustments as needed over 12 months and six months 
respectively, based on remotely transmitted data.7, 25 It was concluded that telemedicine 
supported greater self-decision making among patients and was a driver in better self-care.7 
Studies with the smallest average absolute reduction in HbA1c of 0.29% and 0.26% had similar 
treatment group methods, with clinicians providing individualized feedback when preset alarms 
sounded indicating glucose was outside of target range.14, 21 One study took place in Poland and 
was six months in duration, and one study took place in Italy and was 12 months in duration.14, 21 
These studies were the least proactive regarding engagement with patients, which may explain 
why absolute reductions in HbA1c were among the lowest of the studies included in the current 
review.   
 Continuous Glucose Monitoring 
A total of six studies were included that used CGM, all of which indicated reductions in 
HbA1c within the treatment groups. Average absolute reductions in HbA1c ranged from a high 
of 2.05% to a low of 0.23%. The study with the greatest reported average reduction took place in 
Belgium and showed an average reduction in HbA1c of 2.05%.17 The study did not include a 
control group, therefore a mean difference was not calculated.17 One reason that the reported 
effect may have been larger as compared with other studies is that a specific educational program 
combined with CGM was administered to a very small sample size of six participants who 
completed three months of the study, of which only four participants completed the entire six 
month duration of the study.17 Those who dropped out before six months did so because of 
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technical difficulties with use of the CGM device.17 The intensive nature of the intervention and 
the small sample may have allowed for individualized attention and therefore may not be 
reflective of most interventions used in clinical practice.  
One of the CGM studies used data from the DIAMOND study and had a primary aim of 
identifying whether baseline HbA1c could predict the magnitude of glycemic improvement.18 
The intervention resulted in an average absolute reduction of 1.05% in HbA1c which was among 
the largest reductions reported in our review. A significant number of participants had a high 
baseline HbA1c >9%.18 Results of the study showed a positive relationship between high 
baseline HbA1c and improvements in glycemic status in both the treatment group and the SMGB 
control group.18  
Two studies that indicated similar effectiveness for CGM had different intervention 
methods. One used data from the DIAMOND study and had a primary aim of measuring the 
effect of reduced SMBG testing after adopting CGM.13 All participants were provided with 
guidelines for supplemental treatment decisions based on their CGM data.13 The other study 
focused on a T2D patient population in Singapore with stage three or higher diabetic kidney 
disease not on dialysis.12 Since all participants had diabetic kidney disease, the relatively large 
effect size may have been influenced by improved patient adherence to positive lifestyle choices 
due to greater health risk consequences.12  
Of the CGM studies, one was unique in that the primary aim was to evaluate differences 
in detection of hypoglycemia using conventional methods versus CGM. In this study, the 
reductions in HbA1c were the smallest of the six CGM studies, likely because the participants 
baseline HbA1c levels were lower compared with other studies, and there was not a focus on an 
overall lifestyle intervention based on blood glucose readings.19 
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 Side by Side Comparison 
There are cost differences between the two technologies that should also be taken into 
consideration when selecting the technology that may provide the greatest overall benefit for the 
patient. Private insurance, Medicaid, and Medicare coverage vary greatly between plans and 
from state to state34. Traditional glucose monitoring devices and test strips are most often 
covered, and may or may not contain remote monitoring capabilities. CGM has had limited 
insurance coverage, often requiring that the patient needs multiple daily insulin injections to 
qualify for the option to use this technology. Out of pocket costs can be quite expensive without 
insurance coverage. One recently published study in T1D patients compared the cost of SMBG 
to CGM over a six-month trial.33 Results showed that the average cost for the use of SMBG was 
$7,236 compared to $11,032 for CGM.33 The main difference in these costs was the upfront price 
of the CGM device; overall, the average cost was reduced with longer-term use.33  
The current critical review did not reveal any studies that directly compared remote blood 
glucose monitoring and CGM technologies. Because of this lack of direct comparison, the 
current results should be interpreted with caution. While not an a priori focus of the current 
review, we noticed that there was heterogeneity in the methods and devices used in the remote 
blood glucose monitoring and CGM interventions. Some research reveals differences in 
accuracy, reliability, and precision among devices.16 Differences in technical skills required of 
users to operate the devices should also be taken into consideration when evaluating results of 
our comparisons, as technical difficulties were reported as the cause of participants withdrawing 
from several studies.16, 17 (See Table 3.3)  
While new technology has the potential to support better metabolic improvements in 
diabetes care through more timely and responsive management, it appears that frequent follow-
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up for the remote blood glucose monitoring groups may have resulted in greater reductions in 
HbA1c compared to the CGM group. Algorithm-based treatment plans might also support 
greater reductions in HbA1c by providing more timely lifestyle and medication interventions as 
compared with clinical expertise alone, to ensure a better outcome for patients.  
 Gaps in Current Knowledge  
As indicated previously, the current critical review did not reveal any studies that directly 
compared remote blood glucose monitoring and CGM technologies. Directly comparing both 
methods with the same controls would best answer our study question. Additionally, there was 
heterogeneity in the methods, devices, and controls used in the remote blood glucose monitoring 
and CGM interventions. Future studies should address these limitations by conducting rigorously 
designed randomized controlled trials to directly test the effectiveness of remote blood glucose 
monitoring compared with CGM.    
While evidence clearly shows that improved glycemic control can prevent and mitigate 
diabetic complications, the current standard of care is failing to meet optimal HbA1c targets for 
T2D patients.1, 3, 4 The current critical review suggests that both remote blood glucose monitoring 
and CGM can play an important role for achieving positive clinical outcomes for patients, 
however technical skills by participants might be a limitation. Several studies, particularly with 
use of CGM, reported participants dropping out due to technical difficulties. While the current 
critical review did not compare feasibility or cost of these two different monitoring technologies, 
there are gaps in current knowledge which may be barriers for widespread patient adoption of 
either technology. Future studies should include a comparison of feasibility, cost of care to 
implement the interventions, and cost savings to inform clinical decision making, thereby 
identifying the technology with the greatest overall benefit for the patient. 
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 Conclusion  
The current critical review suggested that both remote blood glucose monitoring and 
CGM are effective for reducing HbA1c in T2D patients when compared to controls. Overall, 
larger effects were seen in the studies that included remote blood glucose monitoring 
interventions as compared with the studies that included CGM. Side by side comparisons of the 
included studies agreed with previous research and indicated a tendency for greater absolute 
reductions in HbA1c where patients had higher starting HbA1c levels, frequent engagement with 
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